10806XAD4
Bridgebio Pharma, Inc.
Could not find a ticker for this position, may be a filing error
A biopharmaceutical company developing medicines for genetic diseases, BridgeBio's approved products include Attruby for a heart condition called ATTR-CM and Truseltiq for bile-duct cancer. Founded in 2015, its name reflects a mission of 'bridging' genetic research to patients, and it runs a hub-and-spoke model where small teams advance each drug. Its experimental oral therapy for achondroplasia was the first-ever treatment for children with the condition to earn the FDA's Breakthrough Therapy designation.
CONVERTIBLEUnderlying: BBIOCUSIP: 10806XAD4HealthcareUS1 derivative reporter
2.25% Convertible Senior Notes due 2029
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
